News & Resources


Webcast ImageWebcast
Orexigen Therapeutics, Inc. at Credit Suisse 24th Annual Healthcare Conference (Replay)
11/11/15 at 2:30 p.m. MT
Orexigen Therapeutics, Inc. at Credit Suisse 24th Annual Healthcare Conference
Wednesday, November 11, 2015 2:30 p.m. MT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCl and bupropion HCl extended release), which is approved in the United States and is being commercialized there by the companys North American partner, Takeda Pharmaceuticals. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolongedMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.04 (1.65%)
Nov 24, 2015 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
11/06/15Orexigen Therapeutics to Present at Credit Suisse 2015 Healthcare ConferencePrinter Friendly Version
11/05/15Orexigen Therapeutics Reports Financial and Business Results for the Third Quarter Ended September 30, 2015Printer Friendly Version
11/03/15Orexigen Announces Naltrexone/Bupropion Data Presentations at ObesityWeek 2015Printer Friendly Version
10/22/15Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2015 Financial Results on November 5, 2015Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.